Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

European and North Indian Cohort of KaWasaki dIsease

Comparison and Performance of Kobayashi and Kawanet IVIg Resistance Scores in a Multi-centric European and North Indian Cohort of KaWasaki dIsease (the KIWI Study)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Kawasaki disease (KD) is currently the leading cause of acquired heart diseases in children in developed countries. Cardiac involvement is the main determinant of the long-term prognosis of these patients, as coronary aneurisms (CAAs) may lead to ischemic heart disease and even sudden death. The current standard of care for KD has consistently reduced CAAs frequency from 25-30% to about 5%. Unfortunately, 10-20% of KD patients results resistant to standard treatment leading to a major risk of cardiac complications. Thus, scoring systems have been constructed in order to identify patients likely to be resistant to IVIG and who may benefit from more aggressive initial therapy. Different scoring scales developed by Kobayashi, Egami et Sano had shown a good sensitivity (77-86%) and specificity (67-86%) in predicting IVIG unresponsiveness in Japanese populations. However, their predictive value was not confirmed by subsequent studies in different ethnic populations. Recently, the French Kawanet group have proposed a IVIG unresponsiveness score that provided good sensitivity and acceptable specificity in a non-Asian KD population even if it was not subsequent validated by an external study. In our study population, the achievement of specificity and sensitivity values for both scores consistent with those reported by the original studies (sensitivity 70% and specificity 80% for Kobayashi and sensitivity 77% and specificity 60% for Kawanet), will be considered a success.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients aged less than 18 years at diagnosis - Diagnosis of KD according to the AHA criteria Who Should NOT Join This Trial: - Patients who do not meet the criteria for KD - Patients for which an alternative infectious diagnosis was not investigated and/or excluded. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients aged less than 18 years at diagnosis * Diagnosis of KD according to the AHA criteria Exclusion Criteria: * Patients who do not meet the criteria for KD * Patients for which an alternative infectious diagnosis was not investigated and/or excluded.

Locations (20)

Universidade Federal do Rio de Janeiro
Rio de Janeiro, Brazil
Children's Hospital Zagreb
Zagreb, Croatia
University Hospital Centre Zagreb, University School of Medicine
Zagreb, Croatia
Le Kremlin-Bicetre University Hospital, Paris-Sud University - CEREMAI
Le Kremlin-Bicêtre, France
Manipal Hospital
Bangalore, India
Postgraduate Institute of Medical Education and Research
Chandigarh, India
Sri Ramachandra Medical Centre
Chennai, India
Amrita Institute of Medical Sciences
Kochi, India
Institute of Child Health
Kolkata, India
Vivekananda Institute of Medical Sciences
Kolkata, India
Meir Medical Centre
Kfar Saba, Israel
ASST Papa Giovanni XXIII
Bergamo, Italy
Spedali Civili
Brescia, Italy
Meyer Children's Hospital IRCCS
Florence, Italy
IRCCS Istituto Giannina Gaslini
Genova, Italy
Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico
Milan, Italy
P.O. "Giovanni Di Cristina"
Palermo, Italy
Università di Torino
Torino, Italy
IRCCS Burlo Garofolo
Trieste, Italy
Beatrix Kinderkliniek, University Medical Center
Groningen, Netherlands